본문 바로가기

Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q2
저널
ENDOCRINE JOURNAL59(10) · pp.919 · 2012
피인용
Web of Science 6
JCR IF
JCR 2011 2.027
ISSN
0918-8959

저자

  1. 김보현제1저자부산대학교, 의과대학, 의학과, KO
  2. Cho, Kyoung Im메리놀병원, Dept Internal Med, KO
  3. Kim, Seong Man메리놀병원, Dept Internal Med, KO
  4. 김지연부산대학교, 의과대학, 의학과, KO
  5. 최보광부산대학교, 부산대학교병원, 대학병원, KO
  6. 강지현부산대학교, 부산대학교병원, 대학병원, KO
  7. 전윤경부산대학교, 의과대학, 의학과, KO
  8. 김상수부산대학교, 의과대학, 의학과, KO
  9. 김성장부산대학교, 의과대학, 의과학과, 내과학교실, KO
  10. Kim, Yong KiKim Yong Ki Internal Med Clin, KO
  11. 김인주부산대학교, 의과대학, 의학과, 내과학교실, KO

초록

This study evaluated the effects of irbesartan and propranolol on thyroid hormone (TH)-induced cardiac functional and structural remodeling. A rat model of thyrotoxicosis was established by daily intraperitoneal injections of L-thyroxine (T-4, 100 mu g/kg) for 4 weeks. Forty Sprague-Dawley rats were randomly divided into four groups (n = 10 each): control group, T-4 group (T-4 alone), T-4 plus irbesartan group (T-4-lrb, 30 mg/kg), and T-4 plus propranolol group (T-4-Pro, 0.5mg/mL of drinking water). Cardiac chamber size and functional parameters were measured by echocardiography and cardiomyocyte diameter. Heart rate (FIR) and cardiac fibrosis were determined. T-4 alone showed significantly increased HR and cardiomyocyte width (25.0 +/- 1.77 vs. 18.8 +/- 0.84 mu m, P<0.001) with fibrosis, reduced left ventricle (LV) longitudinal strain (S-long; -16.0 +/- 6.27 vs. -22.7 +/- 5.19 %, P < 0.001) compared with control. When compared with T-4 alone, T-4-lrb showed significantly improved LV S-long (-21.4 +/- 1.84 vs. -16.0 +/- 6.27%, P=0.017) and reduced cardiomyocyte width (21.0 +/- 1.0 vs. 25.0 +/- 1.77 mu m, P=0.002) with comparable HR (458.4 +/- 24.3 vs. 486.6 +/- 30.1 bpm, P = 0.086). However, T-4-Pro showed significantly reduced HR with improved LV S-long without alteration of cardiomyocyte width and fibrosis compared with T-4 alone. In conclusion, renin-angiotensin system (RAS) blocking by irbesartan could significantly attenuate TH-induced cardiac structural and functional remodeling. However, HR reduction by propranolol could not alternate structural remodeling, which may implicate the RAS as having an important role in thyrotoxic cardiomyopathy beyond tachycardia.

키워드

CardionlyopathyHeart failureThyrotoxicosisRenin-angiotensin systemEchocardiographyINDUCED CARDIAC-HYPERTROPHYRENIN-ANGIOTENSIN SYSTEMCONGESTIVE-HEART-FAILURETHYROID-HORMONEVENTRICULAR HYPERTROPHYADRENERGIC-RECEPTORNERVOUS-SYSTEMHYPERTHYROIDISMRATSFIBROSIS

식별자

WoS UID
000310817300009